CytoDyn to Unveil Updated Leronlimab Data at ESMO 2026
Event summary
- CytoDyn will present updated Phase 2 CLOVER study data on leronlimab in combination with TAS-102 and bevacizumab for mCRC at ESMO Congress 2026.
- Poster presentation scheduled for October 25, 2026, in Madrid, Spain.
- Benjamin Weinberg, M.D., from Georgetown University, will present the findings.
- Study evaluates leronlimab's potential in metastatic colorectal cancer (mCRC).
The big picture
CytoDyn's presentation at ESMO 2026 comes as the biopharmaceutical industry increasingly focuses on combination therapies for difficult-to-treat cancers. The CCR5 receptor, targeted by leronlimab, remains a key area of research in oncology, with potential applications beyond colorectal cancer. The outcome of this study could influence CytoDyn's strategic partnerships and future clinical trial designs.
What we're watching
- Clinical Efficacy
- How the updated CLOVER study data will impact the perceived efficacy of leronlimab in combination with established therapies for mCRC.
- Regulatory Pathway
- Whether positive data could accelerate CytoDyn's regulatory discussions for leronlimab in oncology indications.
- Market Positioning
- The pace at which CytoDyn can differentiate leronlimab in the competitive oncology space.
Related topics